EUROPEAN INFRASTRUCTURE FOR TRANSLATIONAL MEDICINE

To facilitate academic collaborations with industry, we provide research services geared towards biotech SMEs and pharmaceutical companies.

We quickly identify scientific & medical expertise and find the capacity to provide access to the latest technologies and core facilities from within our technology platforms.

By providing feedback to research funders and investigators on issues such as medical needs, market and pipeline overview, regulatory pathway, intellectual property and translational tools, research funders can have more confidence in selecting high potential projects, and investigators can optimise their plans according to the realities of the development pipeline. To this end, EATRIS supports investigators in assessing and optimising the translational feasibility and potential of the projects that research funders are interested in funding.

EATRIS offers a range of services to help researchers strengthen the translational potential of their research proposals such as forming a consortium, joining as a partner, letter of support or leading flagship projects.

EATRIS offers learning solutions targeted to the requirements of different audiences. Benefiting from our large network with key opinion leaders in all areas relevant to translational medicine, we will make sure that the courses offer cutting-edge insights.

Advancing promising technologies and therapies towards clinical application is a complex undertaking. Academic research often lacks easy access to regulatory, therapy development expertise, manufacturing, and healthcare practice, leading to high failure rates. For this reason, the European Joint Programme on Rare Diseases (EJP RD) has initiated a mentoring programme for rare disease researchers.

Addressing regulatory issues is an integral part of bio medicinal development, and their importance will only continue to increase for the foreseeable future. The EATRIS regulatory service and support centre is available to help guide you through this complex world, especially for complex and hybrid products for which clear regulatory guidance may not be available.